← Eichor
Study identifier: NCT06764069 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor

Condition: Diabetes Mellitus  ·  Sponsor: Glucotrack

PhaseNA
Planned participants10
Who can joinAll sexes, 21 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this early first in man clinical trial is to evaluate the safety of an implantable continuous blood glucose monitoring system in participants with Diabetes Mellitus. Safety will be assessed by looking at the absence of procedure or device related adverse events. Additionally, the surgical procedure and device performance will be evaluated. Key Research Questions: 1. Were there any adverse events associated with the insertion of the Sensor Lead? 2. Did Participants experience any device-related adverse events from the Sensor Lead insertion through the 96-hour observation period and subsequent removal of the Sensor Lead? 3. How effectively did the device capture data during the 96-hour wear period?

This description comes directly from the study's public registry record.

Talk to the study team

Sandra L Martha  ·  6198892412  ·  smartha@glucotrack.com

Always discuss trial participation with your own doctor first.

Locations (1)

Instituto do Coração (InCor) |São Paulo, Brazil, BrazilRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06764069